98%
921
2 minutes
20
Background: While minimally invasive enucleation (MIEN) is known for its excellent long-term metabolic outcomes and comparable quality of life (QoL) to that of the general population, previous reports have rarely included exposure, repair, or reconstruction (ERR) of the main pancreatic duct (MPD). This study aims to assess the long-term pancreatic metabolic outcomes and QoL in patients following MIEN involving MPD ERR.
Method: From July 2019 to April 2024, 230 patients were prospectively enrolled. Among them, 93 patients underwent MPD ERR (exposure = 30, suture repair = 17, reconstruction with stenting = 46), while the remaining 137 patients did not have MPD exposure. A textbook outcome specific to MIEN was defined. Metabolic outcomes were assessed, with QoL assessed at the 1-year postoperative mark.
Results: MPD ERR significantly increased perioperative complication rates compared to the non-exposed group, including higher occurrences of clinically relevant postoperative pancreatic fistula (79.6% vs. 41.6%, P<0.001), hemorrhage (16.1% vs. 2.2%, P<0.001), delayed gastric emptying (10.8% vs. 1.5%, P = 0.002), abdominal infection (51.6% vs. 20.4%, P<0.001), and readmission (26.9% vs. 11.7%, P = 0.003). It also impeded the achievement of textbook outcomes (11.8% vs. 51.1%, P<0.001). The MPD ERR group experienced 9 cases of pancreatitis, 14 instances of MPD dilatation, 1 occurrence of stone formation, and 4 cases of pancreatic atrophy, predominantly in the reconstruction with stenting subgroup. However, long-term pancreatic endocrine and exocrine function was well maintained. Compared to the non-exposed group, MPD ERR group showed increased future worries but comparable function and symptom scales.
Conclusion: While MPD ERR significantly increases the complexity of perioperative management following MIEN, it does not affect long-term metabolic outcomes and patient QoL.
Trial Registration: ClinicalTrials.gov (NCTXXXXXXXX).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JS9.0000000000003016 | DOI Listing |
World J Surg Oncol
September 2025
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Inflammation impacts the prognosis of numerous types of tumors. Inflammatory indicators such as the neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-eosinophil ratio (NER) have emerged as potential prognostic markers and are closely correlated with the outcomes of cancer patients. However, the connection between NER and cancer prognosis remains incompletely understood.
View Article and Find Full Text PDFDrug Deliv Transl Res
September 2025
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Diabetes is a metabolic disorder of increasing global concern. Characterized by constantly elevated levels of glucose, severe β-cell dysfunction, and insulin resistance, it is the cause of a major burden on patients if not managed with therapeutic and lifestyle changes. The human body is slowly developing tolerance to many marketed antidiabetic drugs and the quest for the discovery of newer molecules continues.
View Article and Find Full Text PDFOncogene
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The underlying mechanisms leading to ferroptosis hypersensitivity are unknown.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFBull Cancer
September 2025
Clinical Pharmacy Department, Faculty of Pharmacy, Istinye University, Istanbul, Türkiye.
The scientific community has become more enthusiastic about ketogenic diet (KD) to improve the outcomes in medical conditions, including cancer by exploiting the reprogramed metabolism of cancer cells, making the diet a promising candidate as an adjuvant cancer therapy. From this perspective, the aim of this study was to provide a broad overview covering the therapeutic effects, evaluating the clinical evidence of clinical studies underlying the implementation of the KD in the context of cancer treatment and prognosis. A scoping literature search between the years 1990 and 2023 was carried out by using PRISMA guidelines and searching through different databases of the clinical studies supporting the effectiveness and benefits of KD in various carcinomas that could provide findings of evidence on the prognosis and clinical outcomes of cancer treatment.
View Article and Find Full Text PDF